LONDON (Alliance News) - Hikma Pharmaceuticals PLC said Wednesday that it has agreed to sell manufacturing facilities in Bedford, Ohio that were previously owned by Ben Venue Laboratories Inc to Xellia Pharmaceuticals ApS for an undisclosed sum.
Hikma bought the assets from Boehringer Ingelheim in 2014. Since it acquired the site, it has transferred a large number of equipment to its manufacturing facilities in Portugal, Germany and the US.
Xellia has agreed to buy "substantial parts" of the Ben Venue site, including four sterile injectable manufacturing plants which are not currently operational.
"We are very pleased to see that Xellia plans to restart commercial operations at the Ben Venue site, which will create jobs and further support the Bedford community. We have successfully transferred equipment from Ben Venue to our different manufacturing sites, and will continue to benefit from the exceptional capabilities and skills of the Quality and Development Centre and the Bedford R&D teams on-site," said Chairman and Chief Executive Officer Said Darwazah in a statement.
Shares in Hikma were up 1.1% at 2,124.00 pence Wednesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Hikma Pharmaceuticals (HIK)